Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
about
Beyond hypomethylating agents failure in patients with myelodysplastic syndromesTrials with 'epigenetic' drugs: an updatePhase II clinical study of erlotinib for treatment of myelodysplastic syndromes.Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.Epigenetic therapies in MDS and AMLCurrent therapy of myelodysplastic syndromesEpigenetic drugs against cancer: an evolving landscape.Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome.Incidence and Burden of the Myelodysplastic Syndromes.High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndromeDNA Hypomethylation Contributes to Genomic Instability and Intestinal Cancer Initiation.Genetic and epigenetic variants contributing to clofarabine cytotoxicity.Patterns of hospice use in patients dying from hematologic malignanciesWhen is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.The Synergistic Effects of Decitabine Combined with Arsenic Trioxide (ATO) in the Human Myelodysplastic Syndrome Cell Line SKM-1.Lack of cross-resistance to FF-10501, an inhibitor of inosine-5'-monophosphate dehydrogenase, in azacitidine-resistant cell lines selected from SKM-1 and MOLM-13 leukemia cell linesRigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party.NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-Lymphocyte Responses in Patients with Myelodysplastic Syndrome.Cost-effectiveness of treatments for high-risk myelodysplastic syndromes after failure of first-line hypomethylating agent therapy.
P2860
Q26827079-94302B89-DE85-4FBA-A39C-9CFC1D7963E6Q27000542-B86FB16D-0AFA-41A9-8847-5C893E72A6C4Q33414866-62B08A38-853C-43FB-999E-C00476005B88Q33657377-A4FF8EA2-26C9-4729-8637-77F075589236Q33863567-1BAE8336-4D48-4C2D-B874-27B3BE021EACQ34013796-8BFBB0CA-BEDD-48B3-8613-0E363DF91A84Q34431964-42DF3BB1-108E-4669-A139-658B341B8E64Q34628707-BEFF9F25-A5A2-4587-98DA-66D55EF17222Q36006077-7BFDFD4F-39B3-48EF-AC28-701F0E720156Q36654373-1B33AAD8-E9D2-4421-884E-2786762252CAQ36946728-B4CF8431-00A8-40CC-AC88-0ABE0B4B5DA1Q37059820-409BC7ED-4EAF-4591-BED6-A4AA024B485FQ37153800-27D1F40B-1F4A-4AB1-AA08-5B063950992AQ37719210-6FF717F8-C0AD-4AF2-8240-4CF4083AA27BQ38132814-EEFEFB9B-BF05-4446-AF22-447E29EB3890Q38540859-D4C5CD7C-2380-4F28-8005-62146DA5B66FQ38733061-212C7BAA-87AA-4443-ADF7-DFE57E2A089BQ38762107-084A8483-3686-4888-966D-2862B9F3DAD4Q38920820-D1E6174F-203A-4A74-BB21-96BAE9ECC002Q40139200-BEE591AF-95CA-4820-91A8-2B47C488D718Q45624632-2E9A35BE-9BDB-4E27-85A3-188C3D7CE7C0Q47923445-7C7D3E38-D343-4154-B945-1CF35A5FB498Q52901403-B5B6FE33-6865-481A-96D6-387266F5C11C
P2860
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
@en
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
@nl
type
label
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
@en
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
@nl
prefLabel
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
@en
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
@nl
P2860
P1433
P1476
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
@en
P2093
Tapan M Kadia
P2860
P304
P356
10.1053/J.SEMINONCOL.2011.04.011
P577
2011-10-01T00:00:00Z